Curated news and analysis on clinical trials, drug approvals, and medical research.
WELL Health Technologies and HEALWELL AI launched WELLTRUST in Canada to support consent-first, AI-powered clinical trial recruitment. The platform gives patients control over research outreach and integrates DARWEN AI for patient identification.
A 12-week supervised remote exercise program for patients with metastatic renal cell carcinoma undergoing immunotherapy showed significant improvements in health-related quality of life, fatigue, and symptom burden in a case series of 19 patients.
A Phase 1b/2 trial in 28 patients found nivolumab plus modified FOLFIRINOX was well tolerated before surgery in borderline-resectable pancreatic cancer. Seventy-nine percent proceeded to surgery, with complete tumor removal in all resected patients.
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
A study in Nature Medicine found that a single blood test model using plasma %p-tau217 can estimate when Alzheimer’s symptoms are likely to begin. In 603 patients, the model linked biomarker positivity with symptom onset, with a median error of 3.0 to 3.7 years.
TNF-α and MMP-7 levels were higher at diagnosis in adult pulmonary Langerhans cell histiocytosis patients with declining FEV1 than in those with stable FEV1. MMP-7 levels showed a negative correlation with FEV1 values.
Kyowa Kirin and Kura Oncology started a Japanese Phase II registrational study of ziftomenib in adults with relapsed or refractory NPM1-mutated AML. Kyowa Kirin plans to seek regulatory approval in Japan after the trial.
CovaGEN is a conditional latent diffusion framework for de novo design of covalent inhibitors with enhanced drug-likeness and safety. In tests on EGFR T790M and Mpro, generated compounds showed higher probabilities of covalent binding.
Veradermics will host an April 27, 2026 investor call to review topline results from Part A of its Phase 2/3 '302' trial of VDPHL01 in males with pattern hair loss. VDPHL01 is an investigational extended-release oral minoxidil tablet in Phase 3 development.
The FDA approved AstraZeneca’s Saphnelo Pen for once-weekly self-administration in adults with systemic lupus erythematosus. Approval was based on Phase III TULIP-SC results showing reduced disease activity versus placebo.
A meta-analysis of 40 studies found aggressive-variant prostate cancer was linked to shorter progression-free and overall survival. Platinum-based chemotherapy showed higher response rates than non-platinum regimens.
The FDA approved Keytruda and Keytruda Qlex with paclitaxel, with or without bevacizumab, for PD-L1-positive platinum-resistant ovarian-related cancers. The Phase III KEYNOTE-B96 trial showed improved progression-free and overall survival versus placebo.
South Korea’s Ministry of Food and Drug Safety won passage of five legal amendments, including a ban on AI-generated fake-expert ads for health products. The changes also expand state powers over essential drug supply and speed narcotics controls.
Beyond Physician announced the commercial launch of its patent-pending VOICE platform, which uses AI-analyzed physician audio interviews instead of surveys. The company said the platform extracted 560+ data points from a 10-question interview and 9,800+ data points in its first commercial engagement.
A study in the American Journal of Medicine found that U.S. adults with the highest ultraprocessed food intake had higher cardiovascular disease risk. Mean ultraprocessed food intake was 26.1% of total energy.
The Lancet refused a U.S. Senate request for evidence on COVID-19 origins. Purdue Pharma's sentencing was delayed, while insurers moved to reduce prior-authorization paperwork.
More than 2,700 drivers were arrested for drug-related offences in January as authorities expanded roadside inspections and medical testing. Separate road safety checks in Keighley recorded 17 offences, including one drug-driving arrest.
The pharmaceutical manufacturing market is projected to reach $1.24 trillion by 2032, while the continuous manufacturing market is expected to reach $4.2 billion by 2040. Growth is tied to biologic drug demand, digital platforms, automation, and regulatory support.
Anirban Maitra highlighted a talk at NYU Langone Health on milestones in developing RAS tricomplex inhibitors. The presentation also covered ongoing and planned combination approaches.
A UK trial found continuous glucose monitoring improved HbA1c and time in range for adults with type 2 diabetes using basal insulin. Dexcom is also awaiting a Medicare decision on broader CGM coverage for non-insulin users.
